Drug Discovery Software Market Size, Share, Outlook, and Forecast 2021-2026

1
Drug Discovery Software Market Size Status
Top Players Trends Forecast to 2026
2
The market for drug discovery software (such as
ligand-based design, structure-based design,
LIMS, ELN) is driven by rising RD spend and
pipeline, expanding scope and scale, increasing
stringency of testing and regulations, growing
number and size of biotechs, need for increasing
cost efficiencies and reducing time to market,
and the shift to web/cloud-based software. The
global Drug Discovery Software market is valued
at 2 billion in 2020 and is expected to grow at
a CAGR of 14 to cross 3.5 billion by 2025.
This growth is being fueled by rising RD
spending across the globe, need for
cost-efficiency faster time-to-market,
stringent regulatory compliance/reporting,
growing use of AI ML in drug discovery, and
rising demand for novel software solutions
specifically made for biologics/cell gene
therapy. Drug Discovery Software Market Niche
but Fast-Growing Market The drug discovery
software market is niche and expanding quickly,
driven by the growing pressure on the pharma and
biotech companies to cut costs in the research
and preclinical stage of drug development,
decrease timelines and improve transparency
through deep learning software tools.
3

• Large players present in this segment are trying
  to consolidate the market by becoming a one stop
  shop. Moreover, companies are also considering to
  combine their solutions with bioinformatics and
  LIMS tools to have a competitive edge. -
  Executive, Leading Drug Discovery Software
  Provider, US
• Growing Focus on Developing AI/ML platforms for
  Drug Discovery
• The advantages of using big data and AI/ML for
  drug discovery are being recognized by the life
  sciences industry more and more. Several AI/ML
  developments could be seen recently that are
  anticipated to disrupt the current drug discovery
  landscape.
• For instance,
• In Mar 2021, insitro, a ML-driven drug discovery
  and development company raised 400 million. In
  2020, Optibrium launched Cerella, an AI software
  platform for drug discovery.
• Explore Premium Report on Drug Discovery Software
  Market _at_ https//meditechinsights.com/drug-discove
  ry-software-market/

4
Rising Demand for Software Solutions Specifically
Designed for Biologics Biologics are anticipated
to expand rapidly during the drug discovery
process. 50 of drugs currently in the
preclinical phase are biologics. To leverage
growth opportunities, companies are
entering/expanding into biologics software
space. Transition to Web/Cloud-based
Software The drug discovery software industry is
gradually shifting to cloud-based solutions as it
can address most of the issues with on-premise
installations and offer quick deployment, minimum
upfront costs, high flexibility and scalability
making it affordable for even small and medium
size pharma/biotechs, academic research/universiti
es and CROs. Competitive Landscape Analysis of
Drug Discovery Software Market The global drug
discovery software market is highly competitive
and fragmented. Some of the key players include
Dassault Systèmes, LabVantage, PerkinElmer,
Schrodinger, Abbott, Healx, Optibrium, Instem,
Chemical Computing Group, dotmatics, idbs,
Titian, Biovia, Celsius, Genome Biologics,
Atomwise, Standigm, insitro, and CytoReason.
5
For More Detailed Insights, Contact Us
_at_ https//meditechinsights.com/contact-us/ About
Medi-Tech Insights Medi-Tech Insights is a
healthcare-focused business research insights
firm. Our clients include Fortune 500 companies,
blue-chip investors hyper-growth start-ups. We
have completed 100 projects in Digital Health,
Healthcare IT, Medical Technology, Medical
Devices Pharma Services. Contact Ruta
Halde Associate, Medi-Tech Insights 32 498 86 80
79 info_at_meditechinsights.com